drug target. The TB bacteria will be a target for a new Japanese effort to develop treatments for neglected diseases.
Janice Haney Carr / CDC
tens of thousands of new compounds will be screened for efficacy against severe disease
Japan joined the global efforts to contain malaria, tuberculosis, and a variety of tropical diseases a big way. A public-private partnership has recently formed on Saturday will officially announce the agreements on the screen tens of thousands of drug candidates from Japanese banks public and private sectors compounds for treatments for diseases that mainly afflict the poor in developing countries.
The first 11 agreements are the first fruits of a newly formed public-private Global Health Fund Innovative Technology (Ghit Fund). It was created in April and brings together Foreign Affairs of Japan and the ministries of health and well-being, a consortium of five pharmaceutical companies, and the Bill & Melinda Gates Foundation. The Japanese government is a little more than half of the $ 100 million that is committed to Ghit over the next five years; drug manufacturers and the Gates Foundation are contributing the rest. Funding could increase if more companies join the consortium, said BT Slingsby, the fund's CEO and Executive Director.
Slingsby said Japan was a bit behind other nations contributing to global health R and D efforts Although Japan is a major producer of new pharmaceutical products, Japanese companies have not the size and global recognition of US and European pharmaceutical giants. Although Japan was one of the biggest contributors to development aid in recent years, little of this money has already spent in R & D for global health. And major non-governmental organizations dealing with global health concerns are based in the US or Europe, leaving Japan out of the picture.
Returning to the game, looked Ghit a new model rather than creating new nonprofit organizations focused on specific diseases, said Slingsby. "We try to be additive and does not reproduce what is there," he said. They work with nonprofit-World Alliance established goal for TB Drug Development, the Medicines for Malaria Venture (MMV ), and drugs for Neglected Diseases initiative (DNDi) -to help develop drug candidates.
Ghit funding will allow researchers to test compounds from libraries of Japanese drugmakers Eisai, Daiichi Sankyo, Shionogi and Takeda Pharmaceutical, and non-profit institute based in Tokyo of Microbial Chemistry private. the TB Alliance and MMV are looking for drugs to increase current treatments for TB and malaria are losing their effectiveness. DNDi hope to find treatments for three neglected tropical diseases, leishmaniasis, Chagas disease and sleeping sickness. Astellas Pharma is also involved in the initiative.
0 Komentar